Pyridostigmine bromide 180mg modified-release tablets now listed in Part VIIIA of Drug Tariff

Pyridostigmine bromide 180mg modified-release tablets now listed in Part VIIIA of Drug Tariff

November 27, 2017

Pyridostigmine bromide 180mg modified-release tablets entered the Drug Tariff Part VIIIA as a Category C line based on Mestinon retard in November 2017.

Please note that as this item is now listed in the Drug Tariff the way you endorse prescriptions for this line has changed.

No endorsement is needed unless you have been charged out of pocket expenses (OOP). To ensure correct payment for OOP, contractors must endorse:

  • ‘OOP’ or ‘XP’ for paper prescriptions;
  • ‘XP’ for electronic prescription submissions;
  • Details of the claim being made (e.g. postage and packaging); and
  • The total amount being claimed.

For more information on out of pocket expenses see our page here.



Posted in: ,


More Latest News >

October 2018 Category M prices

Category M reimbursement prices for October 2018 can be found here. These show a net overall reduction compared to July 2018...

PSNC CEO webinar now on-demand

Community pharmacy contractors can now access an online recording of PSNC’s recent CEO webinar. Almost 500 people registered for yesterday’s...

Ask PSNC: Flu FAQs

The team at PSNC has received a number of queries on the NHS Flu Vaccination Service 2018/19. Below are some...